Life expectancy in ovarian cancer: why early diagnosis changes everything

Ovarian cancer is one of the most complex oncological conditions in gynaecology, not only because of its biology but because of how it usually presents. Unlike other tumors, its early evolution is silent, which directly conditions life expectancy. In this article, Dr. Juan José Torrent, founder of the Quenet Torrent Institute, reviews the figures we manage today, the factors that genuinely change the prognosis and why the centre where the disease is treated weighs as heavily as the moment of diagnosis.

Today we know that talking about survival in ovarian cancer is not talking about a single figure: it is talking about a clinical scenario that changes radically depending on the moment of diagnosis.

The impact of stage on survival

When the ovarian tumor is detected in a localised stage, confined to the ovary, five-year survival exceeds 90-95%. This places early-stage ovarian cancer among the tumors with the best prognosis in gynaecological oncology.

However, this is not the most common scenario. In clinical practice, a large proportion of patients are diagnosed when the disease has already spread through the abdominal cavity or beyond, forming a peritoneal carcinomatosis of ovarian origin. In these cases, corresponding to stages III and IV, five-year survival drops to roughly 20-40%.

This difference is not marginal: it completely defines the course of the disease and explains why early diagnosis remains the central challenge.

A tumor that is hard to detect in time

Ovarian cancer rarely produces specific symptoms in its early stages. Sensations such as abdominal bloating, digestive changes or pelvic discomfort can appear subtly and be mistaken for benign processes. This lack of clear signals, combined with the absence of effective screening programmes for the general population, contributes to delayed diagnosis.

From a clinical perspective, this calls for a more proactive approach in patients with risk factors or above certain ages, where gynaecological follow-up takes on a strategic role. We expand on this in our guide on how to detect ovarian cancer and its diagnostic tests.

The importance of treatment in specialised centres

In recent years, scientific evidence has confirmed that treatment in highly specialised centres directly influences survival. It is not just about access to advanced technology, but about the accumulated experience in complex oncological surgery and in multidisciplinary decision-making.

The quality of the initial surgery, especially the ability to achieve complete tumor resection through open surgery or, where appropriate, robotic surgery, is one of the most relevant prognostic factors. Add to this the development of targeted therapies and new lines of treatment, alongside the integration of molecular analysis, which allows the strategy to be tailored to the biological characteristics of the tumor.

At the Quenet Torrent Institute we integrate within a single team advanced oncological surgery, medical oncology, molecular diagnostics and access to innovative therapies such as HIPEC (hyperthermic intraperitoneal chemotherapy), which is essential when peritoneal dissemination of ovarian origin is present.

Dr. Juan José Torrent

Founder & Oncological Surgeon

Quenet Torrent Institute

→

"Early-stage ovarian cancer has a survival rate above 90%, but outcomes decline sharply in advanced disease."

— American Cancer Society

"The prognosis of ovarian cancer does not depend solely on stage, but on how it is approached from the very first moment. The combination of expert surgery, molecular diagnosis and a personalised strategy is what truly changes the patient's evolution."

— Oncology Team, Quenet Torrent Institute

Beyond the figures: personalised medicine

Although stage is the single most decisive factor, it is not the only one. Tumor biology, response to treatment and the patient's genetic profile — including BRCA1/BRCA2 mutations — also have a decisive influence. And, above all, we can perform a high-quality surgery — the only prognostic factor we can directly influence — within new strategies such as HIPEC, targeted therapies and innovative regimens that we continuously evaluate from our clinical research line.

That is why life expectancy is no longer interpreted as an isolated statistic, but as the result of an individualised therapeutic strategy.

When the disease affects the peritoneum, we are speaking of peritoneal carcinomatosis of ovarian origin, where the combination of complete cytoreductive surgery plus HIPEC has reshaped survival curves compared with systemic chemotherapy alone.

Conclusion

Ovarian cancer remains a challenge for surgery and oncology, but also a field where advances are making a real difference. The key is still early diagnosis, but also surgery in the hands of the best experts and access to specialised treatment from the outset.

In this context, life expectancy is not just a statistic, but a reflection of how and where the disease is treated. If you need a second opinion on a diagnosis or treatment plan, the Quenet Torrent Institute team is available to evaluate your case and propose the best individualised strategy.